CureVac N.V.

NASDAQ:CVAC  
86.74
+4.95 (+6.05%)
Products

CureVac says European Commission to order up to 405 mln potential COVID-19 doses

Published: 11/16/2020 18:15 GMT
(CVAC) - Contract Spans 225 Million Initial Doses and Option for an Additional 180 Million Doses.
Upfront Payment to Support Financing of Advanced Clinical Development of Cvncov, Ramp-up of European Manufacturing Network and Market Supply Preparations.
Curevac Will Receive an Upfront Payment to Support Advanced Clinical Development of Cvncov and Current Ramp-up of Its Manufacturing Network, As Well As Market Launch and Supply Preparations.
Curevac is Currently Expanding Manufacturing Capacities for Large-scale Manufacturing of Cvncov.
Vaccine Doses Are Expected to Be Produced Both at Curevac's In-house, Gmp-certified Manufacturing Site in Germany and Across a Broad European Manufacturing Network.